{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:45:50Z","timestamp":1780958750742,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K04969"],"award-info":[{"award-number":["23K04969"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.dmpk.2024.101005","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T02:16:15Z","timestamp":1709345775000},"page":"101005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition"],"prefix":"10.1016","volume":"56","author":[{"given":"Makoto","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Masada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-4015","authenticated-orcid":false,"given":"Toshihide","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Omote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-0558","authenticated-orcid":false,"given":"Kentaro","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dmpk.2024.101005_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.36.1.10","article-title":"Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase","volume":"36","author":"Marsden","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101005_bib3","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.11.5.852","article-title":"Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus","volume":"11","author":"Reading","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)12840-1","article-title":"Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes","volume":"277","author":"Kumar","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101005_bib5","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101005_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"10.1016\/j.dmpk.2024.101005_bib7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults","volume":"20","author":"Bartlett","year":"2006","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101005_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.antiviral.2007.06.010","article-title":"Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives","volume":"76","author":"Martinez-Cajas","year":"2007","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101005_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12873","article-title":"Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers","volume":"81","author":"Menon","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2024.101005_bib10","series-title":"package insert","year":"2023"},{"key":"10.1016\/j.dmpk.2024.101005_bib11","series-title":"Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid","year":"2023"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101005_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1248\/bpb.28.130","article-title":"Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats","volume":"28","author":"Kageyama","year":"2005","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101005_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101005_bib15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic Enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101005_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel Pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.dmpk.2024.101005_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128868","article-title":"Discovery of benzyloxyphenyl- and phenethylphenyl-imidazole derivatives as a new class of ante-drug type boosters","volume":"72","author":"Kawai","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101005_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcph.988","volume":"58","author":"Gupta","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101005_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cpdd.145","article-title":"Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor","volume":"4","author":"Cotreau","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101005_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0009-9236(97)90191-0","article-title":"Itraconazole greatly increases plasma concentrations and effects of felodipine","volume":"61","author":"Jalava","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmpk.2024.101005_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical Practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14252\/foodsafetyfscj.D-21-00013","article-title":"Inhibition of CYP3A-mediated midazolam metabolism by Kaempferia Parviflora","volume":"10","author":"Kashiwabuchi","year":"2022","journal-title":"Food Saf (Tokyo)"},{"issue":"9","key":"10.1016\/j.dmpk.2024.101005_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/aps.2009.116","article-title":"Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism","volume":"30","author":"Luo","year":"2009","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101005_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/00498250410001685746","article-title":"Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats","volume":"34","author":"Kanazu","year":"2004","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101005_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4172\/2161-0444.1000495","article-title":"1-Aminobenzotriazole: a mechanism-based cytochrome P450 inhibitor and Probe of cytochrome P450 Biology","volume":"8","author":"de Montellano","year":"2018","journal-title":"Med Chem"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101005_bib26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jps.20538","article-title":"In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance","volume":"95","author":"Strelevitz","year":"2006","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101005_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.dmpk.2016.08.001","article-title":"Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound","volume":"31","author":"Kataoka","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101005_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.dmpk.2024.101005_bib29","article-title":"Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmpk.2024.101005_bib30","unstructured":"NIZORAL\u00ae (ketoconazole) Tablets (Janssen pharmaceuticals, Inc., Titusville, NJ). Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf(Accessed on November 10, 2023)."},{"key":"10.1016\/j.dmpk.2024.101005_bib31","unstructured":"SPORANOX\u00ae (itraconazole) Capsules (Janssen pharmaceuticals, Inc., Titusville, NJ). Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020083s046lbl.pdf(Accessed on November 10, 2023)."},{"issue":"12","key":"10.1016\/j.dmpk.2024.101005_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1359-6446(04)03115-0","article-title":"Compound lipophilicity for substrate binding to human P450s in drug metabolism","volume":"9","author":"Lewis","year":"2004","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101005_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","article-title":"Carboxylesterase in the liver and small intestine of experimental animals and human","volume":"81","author":"Taketani","year":"2007","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcp.2010.09.001","article-title":"Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11","volume":"81","author":"Hatfield","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2024.101005_bib35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10709-010-9438-z","article-title":"Mammalian carboxylesterase 3: comparative genomics and proteomics","volume":"138","author":"Holmes","year":"2010","journal-title":"Genetica"},{"key":"10.1016\/j.dmpk.2024.101005_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","article-title":"The mammalian carboxylesterases: from molecules to functions","volume":"38","author":"Satoh","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101005_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03602530600952164","article-title":"Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes","volume":"39","author":"Hosokawa","year":"2007","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101005_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem Biol Interact"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101005_bib39","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101005_bib40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00129039-200212000-00015","article-title":"Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis","volume":"10","author":"Zhang","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:50:55Z","timestamp":1762368655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S1347436724000119"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101005","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101005"}}